Cybin (NASDAQ:HELP) Issues Quarterly Earnings Results

Cybin (NASDAQ:HELP) announced its quarterly earnings results on Friday. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.19), Zacks reports.

Cybin Stock Up 2.9%

HELP stock opened at $6.09 on Friday. Cybin has a fifty-two week low of $4.81 and a fifty-two week high of $10.59. The company has a debt-to-equity ratio of 0.21, a quick ratio of 8.58 and a current ratio of 8.58.

Analyst Upgrades and Downgrades

Separately, Jefferies Financial Group began coverage on Cybin in a research report on Monday, February 2nd. They set a “buy” rating and a $22.00 price target on the stock. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat, Cybin currently has an average rating of “Buy” and an average target price of $22.00.

Cybin Company Profile

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.